The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
D-type cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation. Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results. Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumour cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione. This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumour cells. The pro-survival function of cyclin D-associated kinase operates in tumours expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumour subsets that undergo cell death and tumour regression upon inhibition of CDK4 and CDK6. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism, represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The cyclin D3/CDK6 kinase complex can phosphorylate 6-phosphofructokinase and pyruvate kinase M2 (Wang et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“This has the effect of pushing glycolytic intermediates into the pentose phosphate and serine pathways, and inhibition of CDK6 (through treatment with palbociclib, ribociclib, or knockdown of CDK6) depletes the antioxidants NADPH and glutathione, increasing ROS and apoptosis.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“These cells express very low levels of cyclin D1, cyclin D2, and CDK4, and the proliferative decision is dependent upon cyclin D3 and CDK6 (Wang et al., 2017; Wolowiec et al., 1996).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Self-citationMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
Self-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationAnastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Cited by
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Self-citationThe Complex Interplay between Antioxidants and ROS in Cancer
Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 626
“Several studies have demonstrated the importance of NADPH generation and reductive capacity for tumorigenesis [74,75].”
BackgroundTargeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Self-citationTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 477
“360,361 To add up, by intravenously administering primed [U-13 C]lactate (completely labeled with carbon-13 at three positions) and utilizing imaging mass spectro-metry (IMS), Bartman et al. mapped TCA cycle fl ux across various tumor models.”
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
“A recent study showed that inhibition of CDK4/6 leads to an RB1dependent increase in reactive oxygen species (ROS) levels, resulting in activation of autophagy, which mitigates the senescence of breast cancer cells in vitro and in vivo (71).”
InfluentialSelf-citationMechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Liu, J., Peng, Y., & Wei, W. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 372
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
“IC50(nM) by cell free assay CDK family kinase complex Palbociclib Ribociclib Abemaciclib CDK4/CyclinD1 11 8 2 CDK4/CyclinD3 9 NR NR CDK6/CyclinD1 NR NR 9.9 CDK6/CyclinD2 15 NR NR CDK6/CyclinD3 NR 39 NR CDK1/CyclinB >10 µM >1.5 µM 1,627 CDK2/CyclinA >10 µM >1.5 µM NR CDK2/CyclinE2 >10 µM >1.5 µM 504 CDK5/p25 >10 µM >1.…”
BackgroundInfluentialMetabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect
Sun, L., Suo, C., Li, S.-T., Zhang, H., & Gao, P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.005 · Cited by 363
Barupal, D. K., & Fiehn, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-15231-w · Cited by 352
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Interconnection between Metabolism and Cell Cycle in Cancer
Icard, P., Fournel, L., Wu, Z., Alifano, M., & Lincet, H. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.12.007 · Cited by 327
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
Topacio, B. R., Zatulovskiy, E., Cristea, S., Xie, S., Tambo, C. S., Rubin, S. M., Sage, J., Kõivomägi, M., & Skotheim, J. M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.020 · Cited by 305
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“[104] Wang H, Nicolay BN, Chick JM, et al.”
BackgroundIntegrating Old and New Paradigms of G1/S Control
Rubin, S. M., Sage, J., & Skotheim, J. M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.08.020 · Cited by 264
“A second possibility is that additional Cdk4/6 targets currently being identified, such as enzymes controlling metabolism (Caillot et al., 2020; Wang et al., 2017), can explain the role of Cdk4/6 in promoting cell-cycle progression and proliferation.”
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258
“In particular, CDK6 emerged as a regulatory hub connecting cell cycle with metabolism (Wang et al., 2017) and transcription (Tigan et al.”
BackgroundGong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236
“…demonstrating that cancers with high levels of CCND3 apoptose in response to CDK4/6i due to the inhibition of a pro-survival metabolic pathway (Wang et al., 2017), which may contribute to the sensitivity of DCAF cells with CCND3 amplification such as Colo-205, and furthermore abemaciclib can…”
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Guiley, K. Z., Stevenson, J. W., Lou, K., Barkovich, K. J., Kumarasamy, V., Wijeratne, T. U., Bunch, K. L., Tripathi, S., Knudsen, E. S., Witkiewicz, A. K., et al. (2019) · Science · doi:10.1126/science.aaw2106 · Cited by 229
“Additional CDK4/6 substrates have been identified more recently (13, 60, 61), and it will be important to explore the role of p27 in their regulation by CDK4/6 phosphorylation.”
Cyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Self-citationFox, D. B., Garcia, N. M. G., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0191-z · Cited by 210
Nebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 187
Cell cycle regulators in cancer cell metabolism
Leal-Esteban, L. C., & Fajas, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165715 · Cited by 179
The Pentose Phosphate Pathway as a Potential Target for Cancer Therapy
Cho, E. S., Cha, Y. H., Kim, H. S., Kim, N. H., & Yook, J. I. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.179 · Cited by 178
“Interestingly, intracellular ROS and CDK6 directly inhibit PKM2 activity via oxidation and phosphorylation, respectively (Anastasiou et al., 2011; Wang et al., 2017).”
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Harris, I. S., Endress, J. E., Coloff, J. L., Selfors, L. M., McBrayer, S. K., Rosenbluth, J. M., Takahashi, N., Dhakal, S., Koduri, V., Oser, M. G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.020 · Cited by 170
“, 2014) and disruption of NADPH homeostasis (Wang et al., 2017).”
BackgroundSeishima, J., Iida, N., Kitamura, K., Yutani, M., Wang, Z., Seki, A., Yamashita, T., Sakai, Y., Honda, M., Yamashita, T., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1879-9 · Cited by 170
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Crucial role of the pentose phosphate pathway in malignant tumors (Review)
Jin, L., & Zhou, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10112 · Cited by 250
“In leukemic cells, the cyclin D3-cyclin dependent kinase 6 (CDK6) phosphorylates PFKP and suppresses its activity (60), thus shifting the glucose‑derived carbon into the PPP.”
BackgroundThe application and prospect of CDK4/6 inhibitors in malignant solid tumors
Du, Q., Guo, X. Y., Wang, M., Li, Y., Sun, X., & Li, Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00880-8 · Cited by 166
“However, Wang’s study showed that approximately 85% of breast cancer cells have normal Rb status, but due to the rare Rb deletion in ER+ breast cancer, it is less sensitive as a predictive marker [79].”
BackgroundSteinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Zhang, J., Simpson, C. M., Berner, J., Chong, H. B., Fang, J., Ordulu, Z., Weiss‐Sadan, T., Possemato, A. P., Harry, S. A., Takahashi, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.026 · Cited by 155
Zacksenhaus, E., Shrestha, M., Liu, J. C., Vorobieva, I., Chung, P. E. D., Ju, Y., Nir, U., & Jiang, Z. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.002 · Cited by 159
The Hippo Pathway Blocks Mammalian Retinal Müller Glial Cell Reprogramming
Rueda, E. M., Hall, B. M., Hill, M. C., Swinton, P. G., Tong, X., Martin, J. F., & Poché, R. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.047 · Cited by 138
Lee, Y., Lahens, N. F., Zhang, S., Bedont, J. L., Field, J. M., & Sehgal, A. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000228 · Cited by 138
Nuclear metabolism and the regulation of the epigenome
Boon, R., da Silveira, G. G., & Mostoslavsky, R. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00285-4 · Cited by 141
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle
Liu, J., Peng, Y., Shi, L., Wan, L., Inuzuka, H., Long, J., Guo, J., Zhang, J., Yuan, M., Zhang, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0372-z · Cited by 126
Yousuf, M., Shamsi, A., Κhan, P., Shahbaaz, M., Alajmi, M. F., Hussain, A., Hasan, G. M., Islam, A., Haque, Q. M. R., & Hassan, M. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103526 · Cited by 120
“CDK6 regulates glucose metabolism by inhibiting the activity of phosphofructokinase (PFK) and pyruvate kinase (PKM) of glycolysis through phosphorylation and subsequently reduces the production of reactive oxygen species (ROS) in cells [9].”
BackgroundQin, L., Dong, S., Yu, J., Ning, X., Xu, K., Zhang, S.-J., Xu, L., Li, B., Li, J., Yuan, Y., et al. (2020) · Metabolic Engineering · doi:10.1016/j.ymben.2020.06.003 · Cited by 114
Chohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 112
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 112
Activated hyaluronan metabolism in the tumor matrix — Causes and consequences
Tammi, M., Oikari, S., Pasonen‐Seppänen, S., Rilla, K. J., Auvinen, P., & Tammi, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.012 · Cited by 102
“In addition, CD44v8-10 stabilizes the cystine transporter xCT on plasma membrane, increases GSH, depletes ROS, and facilitates the growth of gastric cancer [154].”
BackgroundInfluentialMiettinen, T. P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018) · The EMBO Journal · doi:10.15252/embj.201798359 · Cited by 101
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
“In this regard, inhibition of CDK4/6 in cancer cells reduces the levels of the anti-oxidants NADPH and glutathione [9], stabilizes the immunosuppressive ligand PD-L1 (ref.”
G6PD: A hub for metabolic reprogramming and redox signaling in cancer
Yang, H., Stern, A., & Chiu, D. T.-Y. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.08.001 · Cited by 101
“[33] Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, et al.”
BackgroundUshio‐Fukai, M., Ash, D., Nagarkoti, S., de Chantemèle, E. J. B., Fulton, D. J., & Fukai, T. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8161 · Cited by 102
“In proliferating human T cells ( e.g ., acute lymphoblastic leukemia), phosphorylation of PKM2 reduces glycolytic flux and activates the PPP (345).”
De Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
Williams, J. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030041 · Cited by 103
“The mouse clinical trials revealed that in select models, dramatic apoptosis occurs—and these and other studies revealed that cyclin D3-cdk6 have RB1 agnostic substrates involved in metabolism pathways, leading to a novel mechanism of action of this compound and a potential new sub-set of patients to treat [96].”
BackgroundSelf-citationYu, T., Wang, Y., Chen, X., Xiong, W., Tang, Y., & Lin, L. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15489 · Cited by 92
Xiao, G., Yao, J., Kong, D.-P., Ye, C., Chen, R., Li, L., Zeng, T., Wang, L., Zhang, W., Shi, X., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.012 · Cited by 98
Kampen, K. R., Fancello, L., Girardi, T., Rinaldi, G., Planque, M., Sulima, S. O., Loayza‐Puch, F., Verbelen, B., Vereecke, S., Verbeeck, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10508-2 · Cited by 95
Li, Y., Luo, X., Guo, Q., Nie, Y., Wang, T., Zhang, C., Huang, Z., Wang, X., Liu, Y., Chen, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00209 · Cited by 88
HOTAIR , a long noncoding RNA , is a marker of abnormal cell cycle regulation in lung cancer
Liu, M., Zhang, H., Li, Y., Wang, R., Li, Y., Zhang, H., Ren, D., Liu, H., Kang, C., & Chen, J. (2018) · Cancer Science · doi:10.1111/cas.13745 · Cited by 96
“and CDK6 is associated with palbociclib or ribociclib treatment through depletion of the antioxidants NADPH and glutathione.(45)”
BackgroundCDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 90
“Interestingly, tumor types that express other forms of CYCLIN D-CDK4/6 complexes, such as breast cancers in which CDK4 is often in complex with CYCLIN D1, do not undergo apoptosis or exhibit changes in the phosphorylation status of metabolic enzynes in response to CDK4 inhibition [117].”
BackgroundLv, M., Gong, Y., Liu, X., Wang, Y., Wu, Q., Chen, J., Min, Q., Zhao, D., Li, X., Chen, D., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01555-9 · Cited by 89
“CDK6/Cyclin D3 has been shown to phosphorylate and inactivate PFK1 and PKM2, thereby repressing glycolysis in the G 1 phase, 24 while CDK6/Cyclin D1 has been shown to suppress the transcriptional activity of PGC-1 α and NRF1 to attenuate OXPHOS by downregulating the expression of mitochondrial…”
BackgroundInhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy
Yousuf, M., Κhan, P., Shamsi, A., Shahbaaz, M., Hasan, G. M., Haque, Q. M. R., Christoffels, A. G., Islam, A., & Hassan, M. I. (2020) · ACS Omega · doi:10.1021/acsomega.0c03975 · Cited by 81
The paradox of metabolism in quiescent stem cells
Coller, H. A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13608 · Cited by 85
Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis
Guan, Y., Huang, Q., Ai, Y.-L., Chen, Q.-T., Zhao, W., Wang, X., Wu, Q., & Chen, H. (2020) · Oncogene · doi:10.1038/s41388-020-1158-y · Cited by 82
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, F. C., Shajahan‐Haq, A. N., & Swain, S. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.008 · Cited by 84
“Thus, determination of cyclin D3CDK6 levels in primary tumors may allow identification of cancers that are particularly amenable to anti-CDK4/6 therapy (Wang et al., 2017).”
Restriction point regulation at the crossroads between quiescence and cell proliferation
Pennycook, B. R., & Barr, A. R. (2020) · FEBS Letters · doi:10.1002/1873-3468.13867 · Cited by 92
The multifaceted role of cell cycle regulators in the coordination of growth and metabolism
Huber, K., Mestres‐Arenas, A., Fajas, L., & Leal-Esteban, L. C. (2020) · FEBS Journal · doi:10.1111/febs.15586 · Cited by 80
Mitochondrial Metabolism: Yin and Yang for Tumor Progression
Valcárcel-Jiménez, L., Gaude, E., Torrano, V., Frezza, C., & Carracedo, A. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.06.004 · Cited by 80
“On the other hand, cell cycle checkpoint regulators Cyclin D3-CDK6 negatively regulate mitochondrial metabolism by drifting glucose-derived carbons away from the TCA and into the pentose-phosphate pathway, hence supporting the production of antioxidant power [62].”
BackgroundCDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal-Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 76
Reduced ROS ‐mediated antibiotic resistance and its reverting by glucose in Vibrio alginolyticus
Zhang, S., Yang, M., Peng, B., Peng, X., & Li, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15085 · Cited by 82
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
Schmoellerl, J., Barbosa, I. A. M., Eder, T., Brandstoetter, T., Schmidt, L., Maurer, B., Troester, S., Pham, H. T. T., Mohanty, S., Ebner, J., et al. (2020) · Blood · doi:10.1182/blood.2019003267 · Cited by 84
Maik-Rachline, G., Lifshits, L., & Seger, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176102 · Cited by 77
Fuloria, S., Subramaniyan, V., Sundram, K., Kumari, U., Sathasivam, K. V., Meenakshi, D. U., Wu, Y. S., Sekar, M., Chitranshi, N., Malviya, R., et al. (2021) · Antioxidants · doi:10.3390/antiox10010128 · Cited by 93
“Various studies revealed the significance of NADPH reproduction and reduction capacity against tumorigenesis [106].”
BackgroundLessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Xie, Z., Hou, S., Yang, X., Duan, Y., Han, J., Wang, Q., & Liao, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02190 · Cited by 80
Metabolic hallmarks of liver regeneration
Solhi, R., Lotfinia, M., Gramignoli, R., Najimi, M., & Vosough, M. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.06.002 · Cited by 82
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
Apostolidi, M., Vathiotis, I. A., Muthusamy, V., Gaule, P., Gassaway, B. M., Rimm, D. L., & Rinehart, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4190 · Cited by 67
“CDK inhibitors selectively target and dephosphorylate PKM2pS37 Studies focusing on lymphomas have shown that CDK6/cyclinD3 complex can directly phosphorylate PKM2 at S37 (10).”
BackgroundResultInfluentialOshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12102871 · Cited by 71
“Furthermore, combinational inhibition of both CDK4 and CDK6 is expected to have an even greater benefit to the clinical outcomes of PDAC patients [52].”
BackgroundRubio, C., Martínez‐Fernández, M., Segovia, C., Lodewijk, I., Suárez-Cabrera, C., Segrelles, C., López-Calderón, F., Munera-Maravilla, E., Santos, M., Bernardini, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0685 · Cited by 67
Zhang, R., Pan, T. S., Yu, X., Zhang, M., Feng, J., Liu, S., Duan, T., Chen, P., Zhai, B., Chen, X., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00378 · Cited by 59
“If Cyclin D-CDK4/CDK6 complex expression is inhibited, it can inhibit the cell cycle process and promote cell aging, which is expected to become a new therapeutic target (Alquézar et al., 2015; Fan et al., 2017; Wang et al., 2017).”
BackgroundCurrent Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 60
Yan, H., Ren, S., Lin, Q., Yu, Y., Chen, C., Hua, X., Jin, H., Lu, Y., Zhang, H., Xie, Q., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900499rr · Cited by 59
Han, S., Shin, H., Lee, J., Liu, Z., Rabadán, R., Lee, J., Shin, J., Lee, C., Yang, H., Kim, D., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0351-y · Cited by 60
Untargeted metabolomics links glutathione to bacterial cell cycle progression
Hartl, J., Kiefer, P., Kaczmarczyk, A., Mittelviefhaus, M., Meyer, F., Vonderach, T., Hattendorf, B., Jenal, U., & Vorholt, J. A. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0166-0 · Cited by 55
Cysteine as a Carbon Source, a Hot Spot in Cancer Cells Survival
Serpa, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00947 · Cited by 58
“PPP is associated with increased cancer cell survival and proliferation (74, 77), implying the inhibition of phosphofructokinase (mainly PFK1) from glycolysis (78, 79), a direct competitor of glucose-6-phosphate dehydrogenase (G6PD), the limiting enzyme in PPP (75).”
BackgroundA high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells
Ghezzi, C., Wong, A., Chen, B. Y., Ribalet, B., Damoiseaux, R. D., & Clark, P. M. (2019) · Nature Communications · doi:10.1038/s41467-019-13334-8 · Cited by 63
Structural basis for allosteric regulation of pyruvate kinase M2 by phosphorylation and acetylation
Nandi, S., Razzaghi, M., Srivastava, D., & Dey, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015800 · Cited by 56
Effect of post-treatment process of microalgal hydrolysate on bioethanol production
Seon, G., Kim, H. S., Cho, J. M., Kim, M., Park, W.-K., & Chang, Y. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-73816-4 · Cited by 55
Zhou, X., Gao, W., Hua, H., & Ji, Z.-M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.539805 · Cited by 56
“Wang reported in Nature, 2017 that cyclin D3-CDK6 is able to regulate glycolytic pathways (46), which is followed by the emerging studies talking about the directly or indirectly regulation of metabolism by cyclin-CDK counterparts.”
BackgroundZhang, J., Liu, X., Zhou, W., Cheng, G., Wu, J., Guo, S., Jia, S., Liu, Y., Li, B., Zhang, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68224-7 · Cited by 54
The Microenvironment Is a Critical Regulator of Muscle Stem Cell Activation and Proliferation
Nguyen, J. H. V., Chung, J. D., Lynch, G. S., & Ryall, J. G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00254 · Cited by 61
Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia
Gao, X., Qin, S., Wu, Y., Chu, C., Jiang, B., Johnson, R. H., Kuang, D., Zhang, J., Wang, X., Mehta, A. S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143119 · Cited by 50
“To determine the relative amount of the dimeric form of PFKP in both the nucleus and cytosol, we applied ultrafiltration with a 200-kDa-cutoff membrane to separate dimeric (MW 171 kDa) from tetrameric PFKP (MW 342 kDa), as previously reported (9).”
BackgroundMethodInfluentialSelf-citationTargeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 53
“Therefore, inhibition of CDK6 by palbociclib results in activation of PFKP and PKM2, depletion of NADPH and glutathione, increase in ROS, and apoptosis of tumor cells [70].”
BackgroundLin, H., Chen, C.-H., & Fang, S. (2018) · Frontiers in Plant Science · doi:10.3389/fpls.2018.00843 · Cited by 50
“Because of their versatility and ability to detect cell-autonomous responses, protoplast transient expression systems have also been developed and applied to many non-model plants whose transformation platforms are not yet available or for which regeneration of transgenic plants is difficult (Nyman and Wallin, 1992; H…”
BackgroundTerzuoli, E., Nannelli, G., Frosini, M., Giachetti, A., Ziche, M., & Donnini, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20544 · Cited by 47
“com/oncotarget that the down-regulation of Cyclin D3 and CDK6, as found in this work (see Figure 5 panel C trough F), has a strong impact on cancer-specific metabolic pathway (glycolysis), leading to mitochondrial dysfunction [15, 23].”
BackgroundHow yeast coordinates metabolism, growth and division
Ewald, J. C. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.12.012 · Cited by 48
Fueling the Cycle: CDKs in Carbon and Energy Metabolism
Solaki, M., & Ewald, J. C. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00093 · Cited by 49
“showed an interaction of CDK6-Cyclin D3 (G1/Interphase CDK in mammals) with nine out of eleven glycolytic enzymes in human cancer cells (Wang et al., 2017).”
BackgroundA miR‐194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma
Kang, H., Heo, S., Shin, J. J., Ji, E., Tak, H., Ahn, S., Lee, K. J., Lee, E. K., & Kim, W. (2019) · The Journal of Pathology · doi:10.1002/path.5325 · Cited by 48
“As CCND3 is a key factor promoting G1/S transition during the cell cycle [27], thereby participating in tumor progression [28,29], we determined whether the positive effect of PTBP1 on cell cycle progression was mediated by direct targeting of CCND3.”
BackgroundMYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition
Silvis, M. R., Silva, D., Rohweder, R., Schuman, S. S., Gudipaty, S. A., Truong, A., Yap, J. T., Affolter, K. E., McMahon, M., & Kinsey, C. G. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221524 · Cited by 48
“…to phosphorylate rate-limiting metabolic enzymes including phosphofructokinase and pyruvate kinase, which dictate flux through the biosynthetic pentose phosphate pathway and serine biosynthesis pathways, respectively, both of which are supported by autophagy (Wang et al., 2017; Guo et al., 2016).”
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
Zhu, X., Fu, Z., Dutchak, K., Arabzadeh, A., Milette, S., Steinberger, J., Morin, G., Monast, A., Pilon, V., Kong, T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1749 · Cited by 56
CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
Uras, I. Z., Maurer, B., Nivarthi, H., Jodl, P., Kollmann, K., Prchal‐Murphy, M., Feenstra, J. D. M., Zojer, M., Lagger, S., Grausenburger, R., et al. (2019) · Blood · doi:10.1182/blood-2018-08-872648 · Cited by 49
Yousuf, M., Shamsi, A., Queen, A., Shahbaaz, M., Κhan, P., Hussain, A., Alajmi, M. F., Haque, Q. M. R., & Hassan, M. I. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29921 · Cited by 50
The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer
Zhou, W., Wang, W., Liang, Y., Jiang, R., Qiu, F.-S., Shao, X., Liu, Y., Fang, L., Ni, M., Yu, C.-H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39854-y · Cited by 49
“E2F1 is a classical transcription factor, and CDK6 is involved in the transcriptional regulation of gene expression in a kinase-independent manner 17,18,37 , all of which have been reported in promoting cell mitochondrial metabolism, including OXPHOS 38,39 .”
Long, N. P., Jung, K. H., Yoon, S. J., Anh, N. H., Nghi, T. D., Kang, Y. P., YAN, H. H., Min, J. E., Hong, S., & Kwon, S. W. (2017) · Oncotarget · doi:10.18632/oncotarget.22689 · Cited by 47
“Recently, the association between cell cycle and metabolism in the survival mechanism of cancer cells has been demonstrated [35].”
BackgroundLi, S., Zhang, Y., Wang, N., Guo, R., Liu, Q., Lv, C., Wang, J., Wang, L., & Yang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-020-2408-1 · Cited by 50
Relationship Between Loss of Y Chromosome and Urologic Cancers: New Future Perspectives
Russo, P., Bizzarri, F. P., Filomena, G. B., Marino, F., Iacovelli, R., Ciccarese, C., Boccuto, L., Ragonese, M., Gavi, F., Rossi, F., et al. (2024) · Cancers · doi:10.3390/cancers16223766 · Cited by 50
“Notably, FN1 holds significance in cancer metastasis, while CDK6 governs cell proliferation [83,84].”
Metadata
- Authors
- Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., Keibler, M. A., Sicinska, E., Gerdemann, U., Haining, W. N., Roberts, T. M., Polyak, K., Gygi, S. P., Dyson, N. J., & Sicinski, P.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7658
- Pages
- 426-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5516959
- OpenAlex
- W2624626767
- Cited by
- 347
- References
- 37
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 29 · 2023: 43 · 2022: 41 · 2021: 45 · 2020: 61 · 2019: 32 · 2018: 30 · 2017: 15
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, P50CA090381, F32CA165856, T32CA009361, R01CA202634, P01CA080111, R01CA163698, R01CA083688)
- National Institute of General Medical Sciences (R01GM067945)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin D3, CDK6, cyclin-dependent kinases, tumor cell survival, glycolysis, 6-phosphofructokinase, PKM2, pentose phosphate pathway, serine pathway, NADPH, glutathione, reactive oxygen species, oxidative stress, apoptosis, CDK4/6 inhibitors, RB1, patient selection
- MeSH terms
- Aminopyridines, Animals, Cell Cycle, Cell Survival, Female, Glycolysis, Humans, Neoplasms, Pentose Phosphate Pathway, Phosphofructokinase-1, Phosphorylation, Purines, Pyruvate Kinase, Serine, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Xenograft Model Antitumor Assays, Reactive Nitrogen Species, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.